Attendee search 

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology.  The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies.  Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

 

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.

Shield Therapeutics is an independent specialty pharmaceutical company, founded in 2008 with operations in Europe & US. Focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need Shield is led by Carl Sterritt, Chief Executive Officer, an experienced senior pharmaceutical executive with a track record of successful development and commercialisation of pharmaceuticals Shield has successfully raised ~$34m to fund the development of ST10 and PT20 (developed through Phosphate Therapeutics) Lead asset – ST10: Simplifying iron replacement therapy ·         Novel oral iron-based therapy with strong IPR ·         Potential to be the first simple effective oral therapy for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) and non-dialysis dependant chronic kidney disease (CKD) ·         Currently in Phase III trials in patients with IDA in IBD ·         Results are expected to form the basis of a marketing authorisation application (“MAA”) in 2013.  If approved, product commercialisation could commence in 2014 ·         CKD-IDA trials to follow in 2012-2013 ·         Targets potential addressable market of $5bn, with immediate IV market currently reaching  >$1bn pa   PT20: for the treatment of hyperphosphataemia ·         Novel phosphate binder to treat hyperphosphataemia in patients with pre-dialysis and dialysis-dependent CKD ·         In-licensed from Medical Research Council - agreement signed in Q3-11 ·         Early data from in vitro and in vivo trials suggests higher specificity and efficacy than current market leaders and favourable opinion received from UK-MHRA for progression to Phase II clinical trials ·         Approximately 90% of patients with kidney failure require phosphate binder therapy at some point ·         Current market size >$1bn/yr  

BioCrea turns concepts into drug candidates. BioCrea is creating new drugs for the treatment of debilitating diseases of the central nervous system. With industry background and an international leadership team BioCrea provides new, first-in-class drug candidates for pharmaceutical companies.

BioCrea’s ability in inventing new treatments led to partnerships with Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. They validate the company’s technology.

BioCrea is ideally positioned to provide new CNS drugs. Unique expertise and technology was integrated at BioCrea to generate new treatments. BioCrea’s patient-to-screen platform combines patient derived genetic information with the screening process and thus makes the outcome less dependent on biological hypothesis of CNS diseases.